Seznam všech zadavatelů

Zobrazuji zprávy od zadavatele: Neovii Pharmaceuticals

Nalezeno zpráv: 1

Long-term outcomes after standard graft-versus-host disease (GvHD) prophylaxis in hemopoietic cell transplantation from matched unrelated donors strongly support the use of Grafalon® (anti-human-T-lymphocyte immunoglobulin) as standard therapy

26.06.2017 07:45

Zadavatel: Neovii Pharmaceuticals

Nalezeno zpráv: 1